Why was 3M's GAAP loss so large in 2023?

The loss was driven by litigation charges rather than operating weakness. 3M recorded pre-tax charges of about $4.3 billion for the Combat Arms Earplugs settlement and $10.5 billion for the public water systems PFAS settlement, which together reduced EPS by about $20.39. Excluding these and other special items, adjusted EPS was $9.24.

Is 3M's underlying business improving?

Partly. Adjusted operating margin expanded in Q4 2023 to 20.9%, up 1.8 points year-on-year, and adjusted EPS grew 11%. However, organic sales continued to decline (down 1.4% adjusted in Q4 and 3.2% for the full year), with Asia Pacific particularly weak, so top-line growth remains the key weakness.

What does 2024 guidance imply for investors?

Management guided adjusted EPS of $9.35 to $9.75, modestly above 2023's $9.24, with adjusted organic sales growth of flat to 2%. The guidance assumes Health Care stays in the company for the full year and does not include settlement funding costs, so the actual outcome will depend on how the settlements are financed and the timing of the Health Care spin-off.

How will 3M pay for the PFAS and earplug settlements?

3M has not yet selected a funding approach. Options include the planned Health Care business spin-off, which would allow settlement cash to be funded through that transaction, or debt financing. The company estimates full debt financing could reduce adjusted EPS by up to about $0.20, and it has not forecast the incremental net interest expense or the net debt impact.

Is 3M's dividend at risk given the large legal costs?

The dividend appears supported for now. 3M paid $3.3 billion in dividends in 2023, which was covered by adjusted free cash flow of $6.3 billion. Its 2024 guidance for adjusted operating cash flow of $6.5 to $7.1 billion and 95% to 105% free cash flow conversion suggests cash generation can continue to cover dividends, although large settlement payments will absorb a significant share of future cash flow.

MMM 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed January 23, 2024. Cited figures are marked; the original filing is the authoritative source.

3M reported fourth-quarter and full-year 2023 results on January 23, 2024, and the headline numbers are dominated by litigation.

GAAP results were severely negative for the full year: GAAP EPS was a loss of $12.63^a and GAAP operating margin was (27.9)%, driven by pre-tax charges of $4.3 billion for the Combat Arms Earplugs (CAE) settlement and $10.5 billion for the public water systems (PFAS) settlement. Management's adjusted full-year EPS was $9.24, down 6% year-on-year from $9.88, and adjusted operating margin was 20.3% versus 21.1% in 2022. Net costs for significant litigation totaled roughly $14.9 billion for the year on an operating basis, so investors should treat the GAAP loss as largely a one-time legal reserve rather than an operating deterioration.

Operationally, the fourth quarter was stronger than the full year. Q4 GAAP EPS was $1.70^b and adjusted EPS was $2.42, up 11% year-on-year, while adjusted operating margin expanded 1.8 points to 20.9% despite a 1.4-point restructuring headwind. Organic sales declined 1.9% GAAP (1.4% adjusted) in Q4 and 3.2% for the year, with Asia Pacific the main drag.

Cash generation improved meaningfully: full-year operating cash flow rose 19% to $6.7 billion^c and adjusted free cash flow rose 30% to $6.3 billion, largely from working capital and inventory management. Dividends of $3.3 billion were fully covered by free cash flow. Looking ahead, 3M guided 2024 adjusted EPS to $9.35 to $9.75, adjusted organic sales growth of flat to 2%, and adjusted operating cash flow of $6.5 to $7.1 billion.

The guidance assumes the Health Care business remains in the company for the full year and excludes the cash funding needs of the PWS and CAE settlements, which could reduce EPS by up to about $0.20^d if fully debt-financed. The planned Health Care spin-off, targeted for the first half of 2024, is central to how those settlement payments will be funded, so it is the key catalyst to monitor.

02—Key points

Key Highlights

FY2023 GAAP EPS was a loss of $12.63 (GAAP operating margin -27.9%) due to $4.3B CAE and $10.5B PWS PFAS settlement charges; adjusted EPS was $9.24, down 6% year-on-year.
Q4 2023 adjusted EPS rose 11% year-on-year to $2.42 and adjusted operating margin expanded 1.8 points to 20.9%, despite a 1.4-point restructuring headwind and $109M of restructuring net charges.
Sales were $32.7B for FY2023 (down 4.5%) with organic sales down 3.2%; Q4 sales were $8.0B (down 0.8%) with organic sales down 1.9%.
Cash flow strengthened: FY2023 operating cash flow rose 19% to $6.7B and adjusted free cash flow rose 30% to $6.3B, driven by inventory and working capital discipline.
2024 guidance: adjusted EPS of $9.35 to $9.75, adjusted organic sales growth of flat to +2%, and adjusted operating cash flow of $6.5 to $7.1B, with 95% to 105% free cash flow conversion.
Guidance excludes PWS and CAE settlement funding; full debt financing of these settlements could reduce adjusted EPS by roughly $0.20.
Net debt declined to $10.0B from $12.0B at year-end 2022, though total debt rose slightly to $16.0B and shareholders' equity fell to $4.9B from $14.8B due to the litigation charges.

03—Questions

Frequently Asked Questions

Why was 3M's GAAP loss so large in 2023?
The loss was driven by litigation charges rather than operating weakness. 3M recorded pre-tax charges of about $4.3 billion for the Combat Arms Earplugs settlement and $10.5 billion for the public water systems PFAS settlement, which together reduced EPS by about $20.39. Excluding these and other special items, adjusted EPS was $9.24.
Is 3M's underlying business improving?
Partly. Adjusted operating margin expanded in Q4 2023 to 20.9%, up 1.8 points year-on-year, and adjusted EPS grew 11%. However, organic sales continued to decline (down 1.4% adjusted in Q4 and 3.2% for the full year), with Asia Pacific particularly weak, so top-line growth remains the key weakness.
What does 2024 guidance imply for investors?
Management guided adjusted EPS of $9.35 to $9.75, modestly above 2023's $9.24, with adjusted organic sales growth of flat to 2%. The guidance assumes Health Care stays in the company for the full year and does not include settlement funding costs, so the actual outcome will depend on how the settlements are financed and the timing of the Health Care spin-off.
How will 3M pay for the PFAS and earplug settlements?
3M has not yet selected a funding approach. Options include the planned Health Care business spin-off, which would allow settlement cash to be funded through that transaction, or debt financing. The company estimates full debt financing could reduce adjusted EPS by up to about $0.20, and it has not forecast the incremental net interest expense or the net debt impact.
Is 3M's dividend at risk given the large legal costs?
The dividend appears supported for now. 3M paid $3.3 billion in dividends in 2023, which was covered by adjusted free cash flow of $6.3 billion. Its 2024 guidance for adjusted operating cash flow of $6.5 to $7.1 billion and 95% to 105% free cash flow conversion suggests cash generation can continue to cover dividends, although large settlement payments will absorb a significant share of future cash flow.

04—Continue

← View all 8-K filings